

Schedule 3 – Work Plan

In addition to the Accreditation Functions outlined in Schedule 2, the Accreditation Authority's Work Plan for the period 1 July 2024 to 30 June 2025 includes:

Accreditation of programs of study and education providers

- a. accrediting and monitoring of pharmacy degree programs from 19 universities across Australia against the Accreditation Standards 2020 for Board approval
- b. conducting three Accreditation Assessment Team (AAT) visits in FY24
- c. convening meetings of the Accreditation Committee 4 times across the year to consider reports from education providers for notifications of change, re-accreditation activities, conditions on current programs and monitoring of current programs
- d. submitting Accreditation Outcome Notifications (AONs) which describe accreditation decisions made by the Accreditation Committee to the Board after each meeting for the Board's consideration and approval.

Assessment of overseas assessing authorities

- a. outlining an implementation plan for inclusion of Singapore into the Competency Stream by 1 September 2024
- b. working with the Board and Ahpra to streamline registration pathways for overseas qualified pharmacists.

Assessment of overseas qualified health practitioners

- a. continuously improve and update processes for assessment of overseas qualified pharmacists, including content, systems and assessment methodologies
- b. continuing to deliver the KAPS examination via computer-delivery in test centres around the world and Australia and monitoring demand
- c. writing, reviewing and validating new questions for KAPS against an updated examination specifications guide as updated specifications are implemented
- d. redesigning the KAPS exam to deliver this in a new format of one paper (currently 2) from March 2025
- e. convening meetings of the APC examinations committee twice a year in FY25.

Delivery of Intern Written Examination for provisionally registered pharmacists

- a. monitoring the results and outcomes of each mode of delivery of the Intern Written (IW) examination
- b. reviewing the delivery mode in FY25 to determine if both modes (remote and in person) will be offered into the future
- c. continuing to add to the item banks and developing the examination to match the APC/PharmBA Intern Year Blueprint project as necessary.

Accreditation of intern training programs

- a. continuing accrediting and monitoring intern training programs from 6 providers against the Accreditation Standards 2020
- b. monitoring the use and effectiveness of the Workplace Based Assessment tools (WBA).

Special projects

- a. embedding workplace-based assessment (WBA) in pharmacy workplaces - working with the Board on the development and implementation of the Intern Year Blueprint, including evaluation of the WBA tools for the Intern year. The project seeks to enhance pharmacy intern learning by building the capability of pharmacist preceptors and supervising pharmacists to embed WBA in their workplaces

Schedule 4 – Funding arrangements

The Funding Principles below will guide accreditation authorities, National Boards and Ahpra for the 2024/25 financial year initially. These Funding Principles may be reviewed under clause 6.

The Funding Principles are to be applied by accreditation authorities, National Boards and Ahpra when they are considering and agreeing on the funding to be provided to the accreditation authority by the National Board/Ahpra for performance of the Accreditation Functions.

The Funding Principles aim to promote consistency, transparency and accountability for use of registrant fees to fund the Accreditation Function.

Ahpra, in consultation with the National Board, will provide funding through registrant fees to enable the accreditation authority to manage its business and risks by covering some of the indirect costs of activities related to program accreditation, including monitoring.

The following Funding Principles will apply, in addition to the guiding principles and objectives of the National Law, and the Quality Framework for the Accreditation Functions, when an accreditation authority is requesting funding from a National Board/Ahpra (**Funding Request**) and when a National Board/Ahpra decide to provide funding to an accreditation authority (**Funding Decision**):

1. requests for funding should be reasonable and proportionate to the activities being funded.
2. the funding provided by the National Board/Ahpra should cover a proportion of the governance costs related to the accreditation functions.
3. the funding provided by the National Board/Ahpra for the development and review of accreditation standards should be requested and considered separately to the funding of other Accreditation Functions.
4. requests for increases in funding from the previous year should not usually exceed the indexation range applicable to National Board fee increases
5. where an accreditation authority considers an increase in funding above the indexation range is required, it should put the Funding Request and a business case supporting the increase above the indexation range to Ahpra and the National Board for consideration.
6. such Funding Request and business case should be forwarded to Ahpra and the National Board by 10 February or earlier each calendar year to enable them to have sufficient time to properly consider the funding request.
7. Ahpra and the National Board may agree to the requested increase in funding or propose to agree to a lesser amount. Such a proposal and reasons for that proposal should be forwarded to the accreditation authority to enable it to have sufficient time to properly consider the proposed funding amount and reasons.
8. Ahpra and the National Board should agree to provide sufficient funding to enable the accreditation authority to effectively deliver the Accreditation Functions through a combination of funding provided by the National Board/Ahpra and funding from other sources that is provided as a direct result of the accreditation authority being assigned and exercising statutory functions under the National Law.

Item 2 – Funds

Total base funding for 2024/2025 financial year is: \$671,464 (ex GST). The total amount includes \$138,417 (ex GST) specific project funding for embedding workplace-based assessment (WBA) in pharmacy workplaces.

The funding is payable in four instalments on the following dates and in accordance with clause 5.2 of the Head Agreement.

Date	GST exclusive
1 July 2024	\$167,866
1 October 2024	\$167,866
1 January 2025	\$167,866
1 April 2025	\$167,866